Value generated by the multiplier effect of investments by the pharmaceutical industry in Italy: proposals to promote competitiveness and attractiveness


  • Francesca Patarnello Vice-Presidente Market Access & Government Affairs, AstraZeneca Italia, Milan - Italy
  • Emiliano Briante Associate Partner, The European House - Ambrosetti
  • Federico Villa Government Affairs Manager, AstraZeneca Italia, Milan - Italy



Early Access, HTA, Next Generation EU, Pharma industry, Pharma policies, PNRR, R&D


Pharmaceutical industry investments in Italy must be supported with a reform process that promotes simplifications to generate an attractive ecosystem that can enhance innovation. Key actions include facilitating the start-up of clinical trials, promoting public-private partnerships to support technology transfer, integrating data infrastructures to overcome the logic of silos, expanding programs for prevention and early identification of diseases, simultaneous reimbursement for therapy and diagnostic testing, and launching a structural program for early access to therapies.

The total contribution of the sector in the last 10 years to the Italian economy was € 315 bn. Looking at employment (67 thousand people employed in the sector in 2020), it is possible to estimate about 280 thousand jobs activated in Italy just in 2020.

An Altems study quantified a leverage effect of 2.77 in terms of benefits to the Italian NHS from direct investment in clinical research, which means that for every € 1 invested by companies in clinical trials, € 1.77 of additional savings were generated for the NHS. Applying the multiplier on R&D investments of the entire pharmaceutical sector in 2020 (€ 1.6 bn), we could estimate approximately € 4.4 bn in benefits for the NHS. In addition to these benefits there are the noneconomic benefits of clinical research, including early access for patients to innovative therapies, resulting in improved clinical outcomes and quality of life for patients and caregivers in general.


Indicatori Farmaceutici. Farmindustria 2021,2022. Online. (Accessed August 2022)

Pharma outlook 2030: From evolution to revolution. Online. (Accessed July 2022)

Patarnello F, Villa F. New drug pricing criteria in Italy: considerations and proposals to support value and innovation. Glob Reg Health Technol Assess 2021; 8(1):131-3. DOI:

Semplificazione, digital, territorio, etc.: AstraZeneca e società scientifiche a confronto sul futuro del Ssn. Online. (Accessed January 2022)

Camera dei Deputati. Misure sanitarie per fronteggiare l’emergenza coronavirus. Online. (Accessed January 2022)

Relazione sulla ricerca e l’innovazione in Italia. Online. (Accessed August 2022)

Studio strategico sugli impatti e il contributo alla creazione di valore secondo il modello dei 4 Capitali di The European House - Ambrosetti. Elaborazione su dati AstraZeneca, 2021. (Accessed January 2022)

Angerame L., Cicchetti A., Di Paolo M.G., Pluchino G. 2021. Il Valore delle Sperimentazioni Cliniche in Italia: Report 2020. ALTEMS Laboratorio sul Management delle Sperimentazioni Cliniche. Online (Accessed August 2022)

Jommi C, Pantellini F, Stagi L, Verykiou M, Cavazza M. The economic impact of compassionate use of medicines. BMC Health Serv Res. 2021;21(1):1303. PMID:34863155 DOI:

Cavazza M, Costa F, Jommi C. Organizzazione e gestione delle sperimentazioni cliniche. Milano. Egea, 2016.

Piano per la ripresa dell’Europa. Online. (Accessed January 2022)

Piano Nazionale di Ripresa e Resilienza. Online. (Accessed January 2022)

Gehring M, Jommi C, Tarricone T, Cirenei M, Ambrosio G. Towards a more competitive Italy in clinical research: the survey of attitudes towards trial sites in Europe (The SAT-EU StudyTM). Epidemiology, Biostatistics and Public Health 2015;12(1):e10246

Legge 11 gennaio 2018, n. 3, “Delega al Governo in materia di sperimentazione clinica di medicinali nonché disposizioni per il riordino delle professioni sanitarie e per la dirigenza sanitaria del Ministero della salute. Online (Accessed January 2022)

AIFA. Gestione degli studi clinici in Italia in corso di emergenza COVID-19. Online (Accessed January 2022)

Apolone G, Ardizzoni A, Buzzetti G, Clerico MA, Conte P, et al. Early Access in Oncology: Why Is It Needed?. Glob Reg Health Technol Assess. 2019;6(1). DOI:

Jommi C, Armeni P, Costa F, et al. Programmi di early access dei farmaci e managed entry agreement in Italia: i risultati di un Focus Group (programmi di early access e managed entry agreement). Recenti Prog Med. 2021;112(11):749-756. PMID:34782810

Regulation on Health Technology Assessment. Online. (Accessed January 2022)

Improving cancer care through broader access to quality biomarker testing. Online. (Accessed January 2022)

FAVO. Implementare le potenzialità della Medicina di Precisione in Italia. Online. (Accessed January 2022)

DECRETO-LEGGE 6 novembre 2021, n. 152 Disposizioni urgenti per l'attuazione del Piano nazionale di ripresa e resilienza (PNRR) e per la prevenzione delle infiltrazioni mafiose. Online. (Accessed January 2022)

La real world evidence si muove a sostegno del valore dei farmaci. (Accessed January 2022)

Documento di Economia e Finanza 2022. Online (Accessed January 2022)



How to Cite

Patarnello F, Briante E, Villa F. Value generated by the multiplier effect of investments by the pharmaceutical industry in Italy: proposals to promote competitiveness and attractiveness. Grhta [Internet]. 2022 Oct. 5 [cited 2023 May 31];9(1):117-22. Available from:



Point of View


Most read articles by the same author(s)